November 20, 2014

International Women's Day, clinic news, and more...

IAVI International Women's Day 2015

This International Women’s Day, IAVI underscores the enormous toll that HIV/AIDS takes on millions of women and their families, communities and economies, and salutes four remarkable women at the center of the epidemic who are devoting their professional lives to the search for a vaccine.

Click here to read more.

Click here to read a commentary from IAVI CEO Margie McGlynn in Huffington Post India.

Phase I/II Study of T-cell Antigens in African Populations Fully Enrolled
The HIVCORE 004 study is part of a long-term aim to develop an effective HIV-1 vaccine by testing how African populations respond to vaccination with conserved T-cell immunogens. The trial involving 72 healthy adult volunteers in Kenya is a collaboration among the University of Oxford; the European and Developing Countries Clinical Trials Partnership (EDCTP); IAVI; the Karolinska Institute; the University of Nairobi; and Ichor Medical Systems Incorporated.
Phase I Trial of Oral HIV Vaccine Launches
This trial at the University of Rochester Medical Center was designed and funded by Beth Israel Deaconess Medical Center, which received support through a Collaboration for AIDS Vaccine Discovery (CAVD) grant from the Bill & Melinda Gates Foundation (BMGF). IAVI is helping to organize the study through its BMGF-funded Vaccine Product Development Center (VxPDC), which provides services to CAVD grantees.
Enrollment Continues in Trial of Effect of Parasitic Infections on HIV Immune Response
IAVI is collaborating with EUROVAC, MRC-UVRI and UVRI-IAVI in this study to assess how common parasitic infections affect the immune response induced by a DNA + protein HIV vaccine regimen. Preliminary immunology data are anticipated by year-end.
Gladys in labIAVI is partnering with Emory University, eight African Clinical Research Centers (CRCs), and others in a USAID-funded initiative called VISTA (Vaccine Immunology Science and Technology for Africa) to enhance African research capacity and leadership in HIV vaccine design. In particular, VISTA aims to identify vulnerable sites on the surface of HIV to inform design toward vaccine candidates that elicit T cells. VISTA includes traineeships for African scientists in molecular virology (at Emory University) and immunology (at IAVI’s Human Immunology Laboratory at Imperial College London and African CRCs); the inaugural trainee arrived in Atlanta in February. (See related profile marking International Women’s Day.)

IAVI funded two researchers from partner African Gloria and Gershin at ITAPSCRCs to attend the ITAPS Mentoring-of-Mentors Program at the University of California, San Francisco. Gloria Omosa-Manyonyi of the Kenya AIDS Vaccine Initiative (KAVI) and Gershim Asiki of the MRC/UVRI Uganda Research Unit on AIDS will now be able to run this type of training at their home institutions. IAVI has also funded 15 researchers from partner CRCs to pursue advanced degrees, with a second round of candidates to be selected by May 2015.

In continuing efforts to enhance regional input to the organization's research priorities and decision-making, IAVI launched an "investigator-initiated" research program with initial funding for 15 applications from junior and mid-level investigators in Africa, and also welcomed five CRC researchers as official members of IAVI project teams.

IAVI and the Government of India's Translational Symposium Rajat at PodiumHealth Sciences and Technology Institute, our partner in the HIV Vaccine Translational Research Laboratory, hosted a February symposium at which global leaders of the HIV vaccine research and development field engaged 200 research students and post docs, tomorrow's potential discovery scientists. In addition, IAVI and the National AIDS Control Organisation Ministry of Health and Family Welfare gathered Indian and international scientific and civil-society leaders to highlight India's potential as a regional center of excellence for HIV vaccine research and development.
IAVI joined Uganda's task force to advance delivery of HIV prevention in fishing communities following January's launch of a consultative process to ensure broad-based support for this new national strategy.
IAVI chaired the biomedical research working group involved in Kenya's five-year National AIDS Strategic Framework, which officially launched on World AIDS Day, 1 December 2014.
IAVI received US$350,000 from GSK to support implementation of the Human Vaccines Project. Click here to read the announcement.
The Ministry of Foreign Affairs of Denmark awarded IAVI core funding of DKK15M (US$2.5M) over three years (2015-17).
The Bill & Melinda Gates Foundation awarded US$1.2M over three years (2015-17) to support IAVI's European Advocacy program.

Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression, PNAS 16 February 2015.

Creating an African HIV Clinical Research and Prevention Trials Network: HIV Prevalence, Incidence and Transmission, PLoS One 20 January 2015.

Emerging themes for sensitivity training modules of African healthcare workers attending to men who have sex with men: a systematic reviewInternational Health 16 January 2015.

The Abuja +12 Declaration: Implications for HIV response in Africa, African Journal of Reproductive Health December 2014.

Seeking an HIV vaccine: Some progress, but a long road lies ahead, The Health Digest of Health Journalists Network in Uganda October-December 2014.


IAVI Welcomes GSK's Moncef Slaoui to Board 
Chairman of GSK Global Vaccines, Moncef Slaoui, brings a wealth of experience in translating promising research into practical vaccines. Click here to read the full announcement.


Media Contacts


Ethel Makila
+254 71 904 3142 



Hester Kuipers
+31 20 521 0343 



Saif ul Hadi
+91 11 4737 6032 


North America

Rose Catlos
+1 212 847 1049